FDA approves Voxzogo (vosoritide) for children under 5 years with achondroplasia – BioMarin
BioMarin Pharmaceutical Inc. announced that the FDA has approved the supplemental New Drug Application (sNDA) for Voxzogo (vosoritide) to increase linear growth in pediatric patients with achondroplasia with… read more.
